Raloxifene is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women. It was announced on April 17, 2006, that raloxifene is as effective as tamoxifen in reducing the incidence of breast cancer in certain high risk groups of females, though with a reduced risk of thromboembolic events and cataracts in patients taking raloxifene versus those taking tamoxifen. On September 14, 2007, the U.S. Food and Drug Administration announced approval of raloxifene for reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.
There has been criticism in the mainstream oncology press of the way that information about the drug was released.There has been some confusion in the lay media about the meaning of the trial results. There is no specific clinical evidence for the use of raloxifene in the adjuvant treatment of breast cancer over established drugs such as tamoxifen or anastrozole.
The official name of PAX3 gene is “paired box 3". The PAX3 gene belongs to a family of genes that plays a critical role in the formation of tissues and organs during embryonic development. The PAX gene family is also important for maintaining the normal function of certain cells after birth. To carry out these roles, the PAX genes provide instructions for making proteins that attach to specific areas of DNA. By attaching to critical DNA regions, these proteins help control the activity of particular genes. On the basis of this action, PAX proteins are called transcription factors.
During embryonic development, the PAX3 gene is active in cells called neural crest cells. These cells migrate from the developing spinal cord to specific regions in the embryo. The protein made by the PAX3 gene directs the activity of other genes (such as MITF) that signal neural crest cells to form specialized tissues or cell types such as limb muscles, bones in the face and skull (craniofacial bones), some nerve tissue, and pigment-producing cells called melanocytes. Melanocytes produce the pigment melanin, which contributes to hair, eye, and skin color. Melanocytes are also found in certain regions of the brain and inner ear.
Location:
PAX3 Gene is present in human chromosome 2 and its coded from region 222,772,850 to 222,871,943 Complement base pairs with 9 exons, the cytogenetic location 2q35-q37.
PAX3 Protein
Disease
Mutations in PAX3 gene causes Waardenburg syndrome Several PAX3 mutations have been identified in people with Waardenburg syndrome, types I and III. Some of these mutations change one of the chemical building blocks (amino acids) used to make the PAX3 protein. Other mutations lead to an abnormally small version of the PAX3 protein. Researchers believe that all PAX3 mutations have the same effect; they destroy the ability of the PAX3 protein to bind to DNA and regulate the activity of other genes. As a result, melanocytes do not develop in certain areas of the skin, hair, eyes, and inner ear, leading to hearing loss and the patchy loss of pigmentation that are characteristic features of Waardenburg syndrome. Additionally, loss of PAX3 protein function disrupts development of craniofacial bones and certain muscles, producing the limb and facial features that are unique to Waardenburg syndrome, types I and III.
Alterations in the activity of the PAX3 gene are associated with some cases of cancer of muscle tissue (alveolar rhabdomyosarcoma) that occur mainly in adolescents and young adults. Gene activity is altered when the PAX3 gene on chromosome 2 is fused with the FOXO1A gene (also called FKHR) on chromosome 13. This fusion event occurs when segments of chromosomes 2 and 13 are rearranged in certain cells that develop into muscle tissue. The fused PAX3-FOXO1A gene may enhance changes that can lead to cancer, such as uncontrolled cell division and cell growth.
# Arnold K., Bordoli L., Kopp J., and Schwede T. (2006). The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling. Bioinformatics, 22,195-201.
# Schwede T, Kopp J, Guex N, and Peitsch MC (2003) SWISS-MODEL: an automated protein homology-modeling server. Nucleic Acids Research 31: 3381-3385.
# Guex, N. and Peitsch, M. C. (1997) SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modelling. Electrophoresis 18: 2714-2723.
James Alexander Thomson (born December 20, 1958, at Oak Park, Illinois, USA) is an American developmental biologist. He serves as director of regenerative biology at the Morgridge Institute for Research in Madison, Wisconsin, and is a professor at the University of Wisconsin School of Medicine and Public Health. In 2007, he became an adjunct professor in the Molecular, Cellular, and Developmental Biology (MCDB) Department at the University of California, Santa Barbara.[ He is a member of the National Academy of Sciences. In the May 12, 2008, issue of TIME magazine, he was named one of 100 of the most influential people in the world.
In this Frontiers in Cancer Research lecture from UCSB he explores current understanding how human embryonic cells can form any cell in the body and the implications for cancer research.
About Research Group Human and non-human primate embryonic stem cells
Group reported the first derivation of embryonic stem (ES) cells from a non-human primate in 1995, work that led us to the first derivation of human ES cells in 1998. Human ES cells are capable of unlimited undifferentiated proliferation, and yet maintain the ability to form all the cells of the body. Much of our early work focused on developing the basic tools (for example, transfection techniques, homologous recombination, and culture conditions) needed to establish human ES cells as a useful experimental model. My group has also been involved in demonstrating the developmental potential of human ES cells in lineage-specific differentiation (such as blood, trophoblast, neural tissue, and heart). Ultimately, the differentiated derivatives of human ES cells could have important applications in transplantation medicine, and we continue some studies of lineage-specific differentiation in collaboration with UW physician scientists.
The current focus of lab is on understanding the ES cell itself. We wish to understand why this cell can form any cell in the body (pluripotency); how an ES cell chooses between self-renewal and the initial decision to differentiate; what determines which developmental transitions are allowed or not-allowed; and how a differentiated cell with limited developmental potential can be reprogrammed to a pluripotent cell.
Anaphylaxis is defined as "a serious allergic reaction that is rapid in onset and may cause death".[1] It typically results in a number of symptoms including an itchy rash, throat swelling, and low blood pressure. Common causes include insect bites, foods, and medications.
On a pathophysiologic level, anaphylaxis is due to the release of mediators from certain types of white blood cells triggered either by immunologic or non-immunologic mechanisms. It is diagnosed based on the presenting symptoms and signs. The primary treatment is injection of epinephrine, with other measures being complementary.
Vancomycin INN ( /væŋkɵˈmaɪsɨn/) is a glycopeptide antibiotic used in the prophylaxis and treatment of infections caused by Gram-positive bacteria. It has traditionally been reserved as a drug of "last resort", used only after treatment with other antibiotics had failed,[citation needed] although the emergence of vancomycin-resistant organisms means that it is increasingly being displaced from this role by linezolid (Zyvox) available PO and IV and daptomycin (Cubicin) IV and quinupristin/dalfopristin (Synercid) IV.
